Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Varicella-zoster virus vaccine and application thereof

A herpes zoster virus and vaccine technology, applied in the field of vaccines, can solve problems such as research that has not been clinically applied

Pending Publication Date: 2022-07-22
TAIZHOU BIVO BIOTECH CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Due to the strong cytotoxicity of QS21, many studies have not been clinically applied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Varicella-zoster virus vaccine and application thereof
  • Varicella-zoster virus vaccine and application thereof
  • Varicella-zoster virus vaccine and application thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0049] Experimental example 1, gE concentration

[0050] EXAMPLES Vaccines were lysed overnight at room temperature in 0.1 M sodium hydroxide and 0.1% (w / v) sodium dodecyl sulfate buffer. Use BCA colorimetric protein detection kit (Shanghai Biyuntian Biotechnology Co., Ltd.) to detect the gE concentration and calculate the protein loading efficiency.

experiment example 2

[0051] Experimental example 2, nucleic acid concentration

[0052] EXAMPLES Vaccines were lysed overnight at room temperature in 0.1 M sodium hydroxide and 0.1% (w / v) sodium dodecyl sulfate buffer. The nucleic acid concentration was detected and the nucleic acid loading efficiency was calculated using the nucleic acid detection kit Quant-iT OliGreen ssDNA Regent Kit (purchased from Thermo Fisher).

experiment example 3、Q

[0053] Experimental example 3, QS21 concentration

[0054] EXAMPLES Vaccines were lysed overnight at room temperature in 0.1 M sodium hydroxide and 0.1% (w / v) sodium dodecyl sulfate buffer. Using free QS21 as the standard, high performance liquid chromatography (HPLC, purchased from Waters Company) with a 4.6×250 mm C18 column (purchased from Waters Company) was used to measure the content of QS21 encapsulated in the examples and calculate the QS21 loading efficiency.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
polydispersity indexaaaaaaaaaa
Login to View More

Abstract

The invention provides a varicella-zoster virus vaccine and application thereof, and belongs to the technical field of vaccines. The varicella-herpes zoster virus vaccine comprises liposome nano-particles, herpes zoster virus glycoprotein E and an adjuvant, wherein the herpes zoster virus glycoprotein E and the adjuvant are entrapped in the liposome nano-particles; the adjuvant comprises triterpenoid saponin. In the invention, after the herpes zoster virus glycoprotein E (gE) is wrapped by the liposome nanoparticles, antigen presenting cell phagocytosis and efficient antigen delivery can be effectively promoted, and sustained release of the vaccine is realized to continuously stimulate a body to generate specific cellular immune response aiming at VZV-gE. The triterpenoid saponin used in the invention can effectively realize cross presentation of antigen herpes zoster virus glycoprotein E and induce antigen-specific cellular immune response. Moreover, cholesterol rich in the lipid nanoparticles can effectively neutralize the cytotoxicity of the triterpenoid saponin, so that the safety of the vaccine is ensured.

Description

technical field [0001] The invention belongs to the technical field of vaccines, and particularly relates to a varicella-zoster virus vaccine and applications thereof. Background technique [0002] Varicella-Zoster Virus (VZV) spreads all over the world and is highly infectious. So far, only one serotype has been found, and VZV only infects humans in nature. VZV can cause both chickenpox and herpes zoster (HZ). Following primary infection with varicella, the virus can lie dormant in the host's ganglia, and with age, impaired immune function, or immunosuppression, VZV can be reactivated and cause shingles. Globally, the vast majority of adults are at risk of developing shingles and its associated complications. [0003] The Oka strain live attenuated vaccine developed by Japanese Michiaki Takahashi was approved by the FDA in 1995 for inoculating children and adults to prevent chickenpox (inoculation dose of 1000-10000 PFU (plaqueforming unit)), and then Widely used all ove...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/25A61K39/39A61K9/127A61K47/10A61K47/28A61P31/22
CPCA61K39/12A61K39/39A61K9/127A61K47/10A61K47/28A61P31/22A61K2039/55577C12N2710/16734A61K2039/54A61K9/1271A61K9/0019A61K2039/55561A61K2039/55555A61K2039/6018A61P25/00A61P31/20A61K2039/55505
Inventor 不公告发明人
Owner TAIZHOU BIVO BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products